MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Beta-2 adrenoreceptor agonists - short acting

Drug Safety Update

CSM has advised that potentially serious hypokalaemia may result from beta-2 agonist therapy. This may be exacerbated by corticosteroids, theophylline, diuretics and hypoxia. Plasma potassium may need to be monitored in severe asthma

December 2007: Short-acting beta-2 agonists may be associated with myocardial ischaemia

 December 2014: Short-acting beta-2 agonists: restricted use for tocolysis in premature labour

July 2018: Pressurised metered dose inhalers (pMDI): risk of airway  obstruction from aspiration of loose objects

National Guidance:

NG80: Asthma diagnosis, monitoring and chronic asthma management, November 2017 (updated March 2021)

NG115: Chronic obstructive pulmonary disease in over 16s - diagnosis and management, December 2018 (updated July 2019)

BTS/SIGN British Guideline on the management of asthma, July 2019